Pl54
Phase 1
Pl54 is one of 2 therapeutic programs targeting Phenylketonuria (PKU). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in Phenylketonuria (PKU)
#DrugCompanyPhaseTrials
1Pegvaliase
BioMarin PharmaceuticalPhase 3
Pl54
CChongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Pl54. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]